CD40LG and neoplasm: To analyze the total populations of CD4+ and CD8+ T cells that were activated during tumor rejection, we used the maker CD154 (CD40L) for CD4+ T cells [21] and the activation-associated glycoform of CD43 for CD8+ T cells [22].